# Enzalutamide Treatment in COVID-19

> **NCT04475601** · PHASE2 · TERMINATED · sponsor: **Andreas Josefsson** · enrollment: 42 (actual)

## Conditions studied

- COVID-19
- Corona Virus Infection

## Interventions

- **DRUG:** Enzalutamide Pill

## Key facts

- **NCT ID:** NCT04475601
- **Lead sponsor:** Andreas Josefsson
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-15
- **Primary completion:** 2021-03-24
- **Final completion:** 2021-05-29
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** By sponsor, based on DSMB recommendations
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475601, "Enzalutamide Treatment in COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04475601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*